Effect of Clostridium butyricum on Gastrointestinal Infections.

Biomedicines. February 2022;10(2):.

Tadashi Ariyoshi¹, Mao Hagihara², Motomichi Takahashi³, Hiroshige Mikamo⁴

¹ Department of Clinical Infectious Diseases, Aichi Medical University, Nagakute 480-1195, Aichi, Japan.; ² Department of Clinical Infectious Diseases, Aichi Medical University, Nagakute 480-1195, Aichi, Japan.; ³ Department of Clinical Infectious Diseases, Aichi Medical University, Nagakute 480-1195, Aichi, Japan.; ⁴ Department of Clinical Infectious Diseases, Aichi Medical University, Nagakute 480-1195, Aichi, Japan.

Abstract

Clostridium butyricum is a human commensal bacterium with beneficial effects including butyrate production, spore formation, increasing levels of beneficial bacteria, and inhibition of pathogenic bacteria. Owing to its preventive and ameliorative effects on gastrointestinal infections, C. butyricum MIYAIRI 588 (CBM 588) has been used as a probiotic in clinical and veterinary medicine for decades. This review summarizes the effects of C. butyricum, including CBM 588, on bacterial gastrointestinal infections. Further, the characteristics of the causative bacteria, examples of clinical and veterinary use, and mechanisms exploited in basic research are presented. C. butyricum is widely effective against Clostoridioides difficile, the causative pathogen of nosocomial infections; Helicobacter pylori, the causative pathogen of gastric cancer; and antibiotic-resistant Escherichia coli. Accordingly, its mechanism is gradually being elucidated. As C. butyricum is effective against gastrointestinal infections caused by antibiotics-induced dysbiosis, it can inhibit the transmission of antibiotic-resistant genes and maintain homeostasis of the gut microbiome. Altogether, C. butyricum is expected to be one of the antimicrobial-resistance (AMR) countermeasures for the One-health approach.

Keywords

Clostridioides difficile; Clostridium butyricum; Helicobacter pylori; gastrointestinal infection; gut dysbiosis;

Article Tools:

Medline

Email to me

Archives Highlights:

Aseptic protocol breaches are common among veterinary students scrubbing, gowning, and gloving into surgery.
At least 1 aseptic protocol breach (APB) was noted in 46.3% of the 96 procedures observed. The most common mistakes noted were contact of the sterile towel onto nonsterile surfaces (17.7%), contact of the gown with nonsterile surfaces (17.7%), touching sterile objects with bare hands (12.5%), and improper scrubbing technique (17.4%).

Companion animal veterinary personnel have occupational risk for tularemia and One Health role for tularemia prevention in Kansas.
Forty-three percent (47 of 109) of veterinarians reported diagnosing tularemia in cats and 13% (14 of 109) in dogs. Seven percent (8 of 109) of veterinarians reported having had tularemia. When performing procedures with a high risk of exposure, such as lancing abscesses in tularemia suspects, glove use was 100% but additional personal protective equipment was inconsistent, including eye protection (70%) and surgical face mask (59%).

Owner survey suggests cats may be undertreated for pain compared to dogs after an elective ovariohysterectomy or orchiectomy.
Analgesics were prescribed for 19 of 162 (12%) pets: 14 of 88 (16%) dogs and 5 of 74 (6.7%) cats. There was no difference in the prescription of analgesics between dogs and cats after ovariohysterectomy or orchiectomy. 15 of 19 owners reported their compliance in administering analgesics at 78.9%. Owners' subjective assessments showed that 24 of 86 (28%) dogs and 12 of 68 (17%) cats appeared painful at home.

Feline blood donation: Description and adverse reactions from 29 201 donation events between 2019 and 2023.
Adverse reactions were uncommon (0.29%, 2.88/1000 donor events) and most commonly were cardiorespiratory (0.08%, 0.75/1000 donor events) or behavioral (0.06%, 0.62/1000 donor events). The only risk factor significantly associated with adverse reactions was conscious donation, with conscious donors 4.4 times more likely to have an adverse reaction.

Effective treatment with afoxolaner (NexGard) of Trixacarus caviae in a pet guinea pig.
The animal was treated with a single oral dose of 2.50 mg/kg afoxolaner, and the lesions, presence/absence of mites, and intensity of pruritus were evaluated periodically until 2 months post-treatment. A week after the medication, the lesions were milder, but pruritus was still present and was attributed to the healing process. Further examinations showed significant improvement with the complete remission of clinical signs and no mites at the microscopic examination after 4 weeks.